2019•BMJ Evidence-Based MedicineRequires access

EBM verdict: should albendazole be used for treating lymphatic filariasis? No

Igho Onakpoya

Open publisher page 0 citations

Abstract

Although the WHO Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole coadministered with the microfilaricidal drugs, there is no clear rationale. Results of a recent Cochrane review demonstrate that albendazole has no role in the treatment of lymphatic filariasis. Lymphatic filariasis is a debilitating illness of tropical and subtropical regions. It is caused by the roundworm, Wuchereria bancrofti , the main vector of which is the mosquito, and is characterised by fever, lymphoedema, hydrocele and elephantiasis.1 Based on current WHO estimates, over 120 million people globally are infected with lymphatic filariasis,2 and 1.3 billion people are at risk of infection.3 In 2000, the WHO launched the Global Programme to Eliminate Lymphatic Filariasis with the twin aim of stopping the spread of infection and controlling …

About this research paper

What this paper is about

Although the WHO Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole coadministered with the microfilaricidal drugs, there is no clear rationale. Results of a recent Cochrane review demonstrate that albendazole has no role in the treatment of lymphatic filariasis. Lymphatic filariasis is a debilitating illness of tropical and subtropical regions. It is caused by the roundworm, Wuchereria bancrofti , the main vector of which is the mosquito, and is characterised by fever, lymphoedema, hydrocele and elephantiasis.1 Based on current WHO estimates, over 120 million people globally are infected with lymphatic filariasis,2 and 1.3 billion people are at risk of infection.3 In 2000, the WHO launched the Global Programme to Eliminate Lymphatic Filariasis with the twin aim of stopping the spread of infection and controlling …

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Although the WHO Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole coadministered with the microfilaricidal drugs, there is no clear rationale. Results of a recent Cochrane review demonstrate that albendazole has no role in the treatment of lymphatic filariasis. Lymphatic filariasis is a debilitating illness of tropical and subtropical regions. It is caused by the roundworm, Wuchereria bancrofti , the main vector of which is the mosquito, and is characterised by fever, lymphoedema, hydrocele and elephantiasis.1 Based on current WHO estimates, over 120 million people globally are infected with lymphatic filariasis,2 and 1.3 billion people are at risk of infection.3 In 2000, the WHO launched the Global Programme to Eliminate Lymphatic Filariasis with the twin aim of stopping the spread of infection and controlling …

Key concepts: Lymphatic filariasis, Wuchereria bancrofti, Albendazole, Elephantiasis, Filariasis, Hydrocele, Diethylcarbamazine, Mass drug administration

Related papers

Back to paper searchBrowse research topicsOriginal source
EBM verdict: should albendazole be used for treating lymphatic filariasis? No — Research Paper | ScholarLens